XML 53 R39.htm IDEA: XBRL DOCUMENT v3.20.4
Share-Based Compensation (Tables)
6 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of option activity under the Company's equity plans, including the Company's inducement awards, is as follows for the transition period ended December 31, 2020:
(number of shares in millions)Number
of
shares
Weighted
average
exercise
price
Options outstanding at beginning of period4.8 $24.47 
Options granted0.7 13.38 
Less:
Options exercised— — 
Options canceled or expired(0.3)19.12 
Options outstanding at end of period5.2 23.24 
Options exercisable at end of period4.6 24.71 
Options vested and expected to vest5.2 23.24 
Schedule of Valuation Assumptions for Stock Options During the transition period ended December 31, 2020, the valuation assumptions used for stock options were as follows:
Transition Period Ended December 31,
2020
Risk-free interest rate
0.3% - 0.5%
Expected dividend yield
—%
Expected life (in years)
4.75
Derived service period (in years)
1 - 2.6
Expected volatility
73% - 77%
Summary of Stock Options Outstanding
The following table summarizes information about stock options outstanding at December 31, 2020 (number of shares in millions):
Options outstanding and exercisable
Range of
exercise
prices
Number outstanding at December 31,
2020
Weighted
average
remaining
contractual
life (years)
Weighted
average
exercise
price
13.38 - 19.47
1.7 2.92$19.13 
21.29 - 25.39
0.5 0.9823.97 
26.49 - 26.49
1.5 0.7026.49 
27.07 - 36.55
1.5 1.6927.18 
5.2 1.75$24.71 
Schedule of Restricted Stock Units Activity
A summary of the RSU activity under the Company's equity plans, including the Company's inducement awards and RSU awards with performance metrics, is as follows for the transition period ended December 31, 2020:
2020
(number of shares in millions)Number
of
shares
Weighted
average
grant date
fair value
RSUs outstanding at beginning of period2.3 $32.50 
RSUs granted2.1 13.69 
Less:
RSUs vested(0.9)32.22 
RSUs canceled(0.3)31.51 
RSUs outstanding at end of period3.2 $20.56 
Schedule of Share-Based Compensation Expense
Share-based compensation expense recognized and included in the Consolidated Statements of Operations were as follows:
Transition Period Ended December 31,Years Ended June 30,
(in millions)2020202020192018
Cost of molecular diagnostic testing$0.6 $1.2 $0.8 $0.7 
Cost of pharmaceutical and clinical services0.1 0.3 0.2 0.2 
Research and development expense2.4 5.0 5.4 4.3 
Selling, general, and administrative expense11.8 18.7 27.1 21.9 
Total share-based compensation expense$14.9 $25.2 $33.5 $27.1 
Schedule of Unrecognized Share-Based Compensation Cost
The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans.  The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:
(in millions)As of
December 31, 2020
Unrecognized share-based compensation cost$54.3 
Aggregate intrinsic value of options outstanding5.0 
Aggregate intrinsic value of options fully vested0.7 
Aggregate intrinsic value of RSUs outstanding63.1 
Schedule of Intrinsic Value of Options Exercised
The total intrinsic value of options exercised was as follows:
Transition Period Ended December 31,Years Ended June 30,
(in millions)2020202020192018
Total intrinsic value of options exercised$0.5 $8.8 $0.4 $17.0 
Schedule of Shares Purchased and Compensation Expenses for ESPP Shares purchased under and compensation expense associated with the 2012 Plan for the years reported are as follows:
Transition Period Ended December 31,Years Ended June 30,
(in millions)2020202020192018
Shares purchased under the plans0.1 0.3 0.2 0.1 
Plan compensation expense$0.6 $1.7 $1.0 $0.1 
Schedule of Valuation Assumptions for ESPP
The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions:
Transition Period Ended December 31,Years Ended June 30,
2020202020192018
Risk-free interest rate0.2%1.8%2.1%2.1%
Expected dividend yield—%—%—%—%
Expected life (in years)0.50.50.50.5
Expected volatility94%99%55%45%